Psoriatic arthritis: A diagnostic challenge?

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 3, 2010, Pages 407-414

  Buder, K ^a   Wozel, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Arthritis, psoriatic; Psoriasis, diagnosis; Psoriasis, therapy

Indexed keywords

ANTIMALARIAL AGENT; CYCLOSPORIN; GOLD; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; SALAZOSULFAPYRIDINE;

CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; IMAGING; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYARTHRITIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 77956814649     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Moll JM, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Gladman DD: Axial disease in psoriatic arthritis. Curr Rheumatol Rep 2007;9:455-60.
3. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T et al. Epidemiology of psoriatic arthritis in the population of the united states. J Am Acad Dermatol 2005;53:573.
4. Reich K, Kruger K, Mossner R, Augustin M Epidemiology and clinical pattern of psoriatic arthritis in germany: A prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009;160:1040-7.
5. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study. Arthritis Rheum 2009;61:233-9.
6. Roberts ME, Wright V, Hill AG, Mehra AC. Psoriatic arthritis. Follow-up study. Ann Rheum Dis 1976;35:206-12.
7. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12. (Pubitemid 20213507)
8. Jones SM, Armas JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: Outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol 1994;33:834-9. (Pubitemid 24283222)
9. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-yr prospective study. Rheumatology (Oxford) 2003;42:778-83. (Pubitemid 37220911)
10. Stern RS. The epidemiology of joint complaints in patients with psoriasis. J Rheumatol 1985;12:315-20.
11. Scarpa R, Cosentini E, Manguso F, Oriente A, Peluso R, Atteno M et al. Clinical and genetic aspects of psoriatic arthritis "Sine psoriasis". J Rheumatol 2003;30:2638-40.
12. Goiter S, van der Heijde DM, van der Linden S, Houben H, Rethans JJ, Scherpbier AJ et al. Psoriatic arthritis: performance of rheumatologists in daily practice. Ann Rheum Dis 2002;61:219-24.
13. Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol 1994;33:133-8. (Pubitemid 24051604)
14. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
15. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999;42:1080-6.
16. Kerkhof PCMvd: Textbook of psoriasis. Oxford, Malden, MA, USA: Blackwell Science; 1999.
17. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (psa) - an analysis of 220 patients. Q J Med 1987;62:127-41. (Pubitemid 17042878)
18. McGonagle D, Benjamin M, Tan AL. The pathogenesis of psoriatic arthritis and associated nail disease: Not autoimmune after all? Curr Opin Rheumatol 2009;21:340-7.
19. Scarpa R, Soscia E, Peluso R, Atteno M, Manguso F, Del Puente A et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol 2006;33:1315-9. (Pubitemid 44025146)
20. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in spondylarthropathies: A systematic literature review. Ann Rheum Dis 2008;67:955-9 (Pubitemid 351956657)
21. Durrani K, Foster CS. Psoriatic uveitis: A distinct clinical entity? Am J Ophthalmol 2005;139:106-11.
22. Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis 1976;35:354-56.
23. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-93.
24. Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: Roles of inflammation and dyslipidemia. J Autoimmun 2007;28:69-75. (Pubitemid 46670686)
25. Han C, Robinson DW, Jr., Hackett MV, Paramore LC, Fraeman KH, Bala MV. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72.
26. Boehncke WH, Boehncke S. Cardiovascular morbidity in psoriasis: Epidemiology, pathomechanisms, and clinical consequences. G Ital Dermatol Venereol 2008;143:307-13.
27. Offidani A, Cellini A, Valeri G, Giovagnoni A. Subclinical joint involvement in psoriasis: Magnetic resonance imaging and x-ray findings. Acta Derm Venereol 1998;78:463-5. (Pubitemid 28505965)
28. Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: An early synovitis clinic experience. Rheumatology (Oxford) 2003;42:1460-8. (Pubitemid 37508919)
29. Helliwell PS, Porter G. Sensitivity and specificity of plain radiographic features of peripheral enthesopathy at major sites in psoriatic arthritis. Skeletal Radiol 2007;36:1061-6.
30. Kane D, Greaney T, Bresnihan B, Gibney R, FitzGerald O. Ultrasonography in the diagnosis and management of psoriatic dactylitis. J Rheumatol 1999;26:1746-51. (Pubitemid 29367315)
31. Weiner SM, Jurenz S, Uhl M, Lange-Nolde A, Warnatz K, Peter HH et al. Ultrasonography in the assessment of peripheral joint involvement in psoriatic arthritis : A comparison with radiography, MRI and scintigraphy. Clin Rheumatol 2008;27:983-9.
32. Gisondi P, Tinazzi I, El-Dalati G, Gallo M, Biasi D, Barbara LM et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: A hospital-based case-control study. Ann Rheum Dis 2008;67:26-30.
33. McQueen F, Lassere M, Ostergaard M. Magnetic resonance imaging in psoriatic arthritis: A review of the literature. Arthritis Res Ther 2006;8:207.
34. Hahn K, Thiers G, Eissner D, Holzmann H. [bone scintigraphy in psoriasis (author's transi)]. Nuklearmedizin 1980;19:178-86.
35. Buskila D, Langevitz P, Gladman DD, Urowitz S, Smythe HA. Patients with rheumatoid arthritis are more tender than those with psoriatic arthritis. J Rheumatol 1992;19:1115-9.
36. Scarpa R, Cuocolo A, Peluso R, Atteno M, Gisonni P, Iervolino S et al. Early psoriatic arthritis: The clinical spectrum. J Rheumatol 2008;35:137-41.
37. Lindqvist UR, Alenius GM, Husmark T, Theander E, Holmstrom G, Larsson PT. The Swedish early psoriatic arthritis register - 2-year followup: A comparison with early rheumatoid arthritis. J Rheumatol 2008;35:668-73. (Pubitemid 351500064)
38. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
39. Bogliolo L, Alpini C, Caporali R, Scire CA, Moratti R, Montecucco C. Antibodies to cyclic citrullinated peptides in psoriatic arthritis. J Rheumatol 2005;32:511-5. (Pubitemid 40381424)
40. Inane N, Dalkilic E, Kamali S, Kasapoglu-Gunal E, Elbir Y, Direskeneli H et al. Anti-ccp antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007;26:17-23. (Pubitemid 46020016)
41. Morozzi G, Bellisai F, Fioravanti A, Galeazzi M. Absence of anti-cyclic citrullinated peptide antibodies in erosive osteoarthritis: Further serological evidence of the disease as a subset of osteoarthritis. Ann Rheum Dis 2005;64:1095-6.
42. Candia L, Marquez J, Gonzalez C, Santos AM, Londono J, Valle R et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol 2006;12:226-9.
43. Calzavara PG, Cattaneo R, Franceschini F, Tosoni C, Martinelli M, Carlino A. Antinuclear antibodies in psoriatic arthritis and its subgroups. Acta Derm Venereol Suppl (Stockh) 1989;146:31-2. (Pubitemid 20013734)
44. Johnson SR, Schentag CT, Gladman DD. Autoantibodies in biological agent naive patients with psoriatic arthritis. Ann Rheum Dis 2005;64:770-2.
45. Rahman P, Elder JT. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii37-39; discussion ii 40-31.
46. Gladman DD, Anhorn KA, Schachter RK, Mervart H. Hla antigens in psoriatic arthritis. J Rheumatol 1986;13:586-92.
47. Armstrong RD, Panayi GS, Welsh KI. Histocompatibility antigens in psoriasis, psoriatic arthropathy, and ankylosing spondylitis. Ann Rheum Dis 1983;42:142-6.
48. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005;64 Suppl 2:ii3-8.
49. McGonagle D, Tan AL. Are the classification criteria for psoriatic arthritis better than existing criteria for diagnosing psoriatic arthritis? Comment on the article by taylor et al. Arthritis Rheum 2007;56:699-700; author reply 700.
50. Chandran V, Schentag CT, Gladman DD. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum 2007;57:1560-3. (Pubitemid 350308858)
51. Helliwell PS: GRAPPA - group for research and assessment of psoriasis and psoriatic arthritis, stockholm, May/June 2006. J Rheumatol 2007;34:214-9.
52. Mody E, Husni ME, Schur P, Qureshi AA. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: A dermatology: Rheumatology clinic experience. Br J Dermatol 2007;157:1050-1.
53. Korting GW, Kaffarnik H. [serum uric acid increase in skin disease patients, especially in psoriasis patients.]. Dermatol Wochenschr 1958;138:1359-62.
54. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999;135:1490-3.
55. Lundquist CD, Aronson IK, Henderson TW, Skosey JL, Solomon LM. Psoriasis and normouricemic gout. Dermatologica 1982;164:104-8.
56. Calin A. Keratodermia blennorrhagica and mucocutaneous manifestations of reiter's syndrome. Ann Rheum Dis 1979;38 Suppl 1:suppl 68-72.
57. Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58:224-31.
58. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21.
59. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64 Suppl 2:ii74-77.
60. Klinkhoff AV, Gertner E, Chalmers A, Gladman DD, Stewart WD, Schachter GD et al. Pilot study of etretinate in psoriatic arthritis. J Rheumatol 1989;16:789-91.
61. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke WH, Follmann M et al. Evidence-based (s3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007;5 Suppl 3:1-119. (Pubitemid 47033875)
62. Clegg DO, Reda DJ, Mejias E, Cannon GW, Weisman MH, Taylor T et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 1996;39:2013-20.
63. Salvarani C, Macchioni P, Olivieri I, Marchesoni A, Cutolo M, Ferraccioli G et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-82. (Pubitemid 32947875)
64. Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
65. Nash P, Thaci D, Behrens F, Falk F, Kaltwasser JP. Leflunomide improves psoriasis in patients with psoriatic arthritis: An in-depth analysis of data from the topas study. Dermatology 2006;212:238-49.
66. Mahrle G, Schulze HJ, Farber L, Weidinger G, Steigleder GK. Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995;32:78-88.
67. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin a and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study. Clin Exp Rheumatol 1995;13:589-93.
68. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs - comparison of drugs and adverse reactions. J Rheumatol 2008;35:472-6.
69. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984;27:376-81.
70. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: Results from a longitudinal observational cohort. J Rheumatol 2008;35:469-71. (Pubitemid 351374423)
71. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol 2008;27:823-6.
72. Gladman DD. Traditional and newer therapeutic options for psoriatic arthritis: An evidence-based review. Drugs 2005;65:1223-38.
73. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: Findings of the infliximab multinational psoriatic arthritis controlled trial (impact). J Rheumatol 2008;35:869-76.
74. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89.
75. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72. (Pubitemid 38924405)
76. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. Methotrexate vs. Placebo in patients with psoriasis (champion). Br J Dermatol 2008;158:558-66.
77. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
78. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40.
79. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
80. Pipitone N, Kingsley GH, Manzo A, Scott DL, Pitzalis C. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford) 2003;42:1138-48. (Pubitemid 37258474)
81. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: Overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64.
82. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The pase questionnaire: Pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol 2007;57:581-7. (Pubitemid 47384917)
83. McGonagle D, Tan AL, Benjamin M. The Nail as a musculoskeletal appendage - Implication for an improved understanding of the link between psoriasis and arthritis. Dermatology 2009;218:97-102
84. Gladman DD, Farewell VT, Nadeau C. Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model. J Rheumatol 1995;22:675-9.
85. Olivieri I, Padula A, Scarano E, Scarpa R. Dactylitis or "Sausage-shaped" Digit. J Rheumatol 2007;34:1217-22.